Home
Live Updates
Ipsen : and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders -Today at 11:14 am : comparemela.com
Ipsen : and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders -Today at 11:14 am
Ipsen obtains exclusive options to Spherical Nucleic Acids currently under discovery evaluation for Huntington's disease and Angelman syndrome
Exicure...
Related Keywords
United States ,
Chicago ,
Illinois ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
France ,
Crawford ,
South Lanarkshire ,
Philippe Lopes Fernandes ,
Ipsen Euronext ,
David Giljohann ,
Exicure Inc ,
Nasdaq ,
Spherical Nucleic Acids ,
Chief Business Officer ,
Chief Executive Officer ,
Reviews Drug Discovery ,
Markets ,
comparemela.com © 2020. All Rights Reserved.